Search results below include Worst Pills, Best Pills Newsletter Articles where your
selected drug is a secondary subject of discussion.
July 2025
In January 2025 the FDA approved suzetrigine (JOURNAVX), an oral drug, for treatment of moderate to severe pain in adults. Because the drug has only been compared with hydrocodone/acetaminophen and placebo in short-term clinical studies and its adverse effects are not fully understood, Public Citizen’s Health Research Group has classified suzetrigine as Do Not Use for Seven Years.
September 2020
In recent years, there has been a surge in the use of compounded topical pain creams as an alternative to oral pain medications, such as non-steroidal anti-inflammatory drugs and opioids. However, a committee of experts convened by the National Academies of Sciences, Engineering, and Medicine recently concluded that there is a lack of evidence to support the safety and effectiveness of these compounded products.